Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women

Clinical Therapeutics

Volumn 21, Issue 6, 1999, Pages 966-981

  Henry, Dan C ^a   Nenad, Robert C ^b   Iravani, Abdollah ^c   Tice, Alan D ^d   Mansfield, Debra L ^e   Magner, David J ^f   Dorr, Mary Beth ^e   Talbot, George H ^e  

^a Foothill Family Clinic   (United States)

^b St Luke's Medical Center   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d Infectious Ltd   (United States)

^e SANOFI   (France)

^f Astra Pharmaceuticals   (United States)

Author keywords

Anti infective agent; Ciprofloxacin; Sparfloxacin; Uncomplicated urinary tract infection

Indexed keywords

CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHOTOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL; THRUSH; URINARY TRACT INFECTION; VERTIGO;

EID: 0032766826     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80018-6     Document Type: Article

References (33)

1. 1. Elder NC. Acute urinary tract infection in women. Postgrad Med. 1992;92:159-172.
2. 2. Stamm WE, Hooten TM. Management of urinary tract infections in adults. NEJM. 1993;329:1328-1334.
3. 3. Hatton J, Hughes M, Raymond CH. Management of bacterial urinary tract infections in adults. Ann Pharmacother. 1994; 28:1264-1272.
4. 4. Kunin CM. Urinary tract infections in females. Clin Infect Dis. 1994;18:1-12.
5. 5. Williams DN. Urinary tract infections. Postgrad Med. 1996;99:189-204.
6. 6. Hooten TM, Stamm WE. Management of acute uncomplicated urinary tract infection in adults. Med Clin North Am. 1991; 75:339-357.
7. 7. Kim ED, Schaeffer AJ. Antimicrobial therapy for urinary tract infections. Semin Nephrol. 1994;14:551-569.
8. 8. Ward TT, Jones SR. Genitourinary tract infections. In: Reese RE, Betts RF, eds. A Practical Approach to Infectious Disease. 3rd ed. Boston: Little, Brown and Company; 1991:257-275.
9. 9. Rubin RH, Beam TR Jr, Stamm WE. An approach to evaluating antibacterial agents in the treatment of urinary tract infection. Clin Infect Dis. 1992;14(Suppl 2):S246-S251.
10. 10. Iravani A. Advances in the understanding and treatment of urinary tract infections in young women. Urology. 1991;37:503-511.
11. 11. Iravani A, Bischoff W. Antibiotic therapy for urinary tract infections. Am J Med. 1992;92(Suppl 6A):95S-100S.
12. 12. Mizuki Y, Fujiwara I, Yamaguchi T. Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. J Antimicrob Chemother. 1996;37(Suppl A):41-55.
13. 13. Montay G. Pharmacokinetics of sparfloxacin in healthy volunteers and patients: A review. J Antimicrob Chemother. 1996;37(Suppl A):27-39.
14. 14. Naber KG, Di Silverio F, Geddes A, Guilbert J. Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection. J Antimicrob Chemother. 1996;37(Suppl A): 135-144.
15. 15. Nakamura S, Minami A, Nakata K, et al. In vitro and in vivo antibacterial activities of AT-4140, a new broad spectrum quinolone. Antimicrob Agents Chemother. 1989;33: 1167-1173.
16. 16. Paradelis AG, Delidou K, Grigoriadou A, et al. The antimicrobial activity of sparfloxacin, a new quinolone. Drugs. 1995;49(Suppl 2): 238-239.
17. 17. Baquero F, Cantón R. In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens. J Antimicrob Chemother. 1996;37(Suppl A):1-18.
18. 18. Chin N-X, Gu J-W, Yu K-W, et al. In vitro activity of sparfloxacin. Antimicrob Agents Chemother. 1991;35:567-571.
19. 19. Patron C, Baquero F, Montcagudo J-L, Vincente M-F. Postantibiotic effect of sparfloxacin. Eur J Clin Microbiol Infect Dis. 1991;Special Issue:537-540.
20. 20. Grubbs NC, Schultz HJ, Henry NK, et al. Ciprofloxacin versus trimethoprim-sulfamethoxazole: Treatment of community-acquired urinary tract infections in a prospective, controlled, double-blind comparison. Mayo Clin Proc. 1992;67:1163-1168.
21. 21. Approved standard M2-A5. In: Performance Standards for Antimicrobial Disk Susceptibility Tests. 5th ed. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1993. Vol. 13. No. 24.
22. 22. Approved Standard M7-A3. In: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 3rd ed. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1993. Vol. 13, No. 25.
23. 23. Norrby SR. Short-term treatment of uncomplicated lower urinary tract infections in women. Rev Infect Dis. 1990;12:458-467.
24. 24. Neringer R, Forsgren A, Hansson C, et al. Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: Three-day versus seven-day treatment. Scand J Infect Dis. 1992;24:773-780.
25. 25. Stein GE, Philip E. Comparison of three-day temafloxacin with seven-day ciprofloxacin treatment of urinary tract infections in women. J Fam Pract. 1992;34:180-184.
26. 26. Iravani A. Multicenter study of single-dose and multiple-dose fleroxacin versus ciprofloxacin in the treatment of uncomplicated urinary tract infections. Am J Med. 1993;94(Suppl 3A):89S-96S.
27. 27. Iravani A, Tice AD, McCarty J, et al. Short-course ciproflox treatment of acute uncomplicated urinary tract infection in women. Arch Intern Med. 1995;155:485-494.
28. 28. Hooten TM, Johnson C, Winter C, et al. Single-dose and three-day regimens of ofloxacin versus trimethoprim-sulfamethoxazole for acute cystitis in women. Antimicrob Agents Chemother. 1991;35:1479-1483.
29. 29. Nicolle LE, DuBois J, Martel AY, et al. Treatment of acute uncomplicated urinary tract infections with 3 days of lomefloxacin compared with treatment with 3 days of norfloxacin. Antimicrob Agents Chemother. 1993;37:574-579.
30. 30. Just PM. Overview of the fluoroquinolone antibiotics. Pharmacotherapy. 1993;13 (Suppl 2 pt 2):4S-17S.
31. 31. Rubinstein E. Safety profile of sparfloxacin in the treatment of respiratory tract infections. J Antimicrob Chemother. 1996;37 (Suppl A):145-160.
32. 32. Data on file. Collegeville, Pa: Rhône-Poulenc Rorer Pharmaceuticals Inc.; 1996.
33. 33. Jaillon P, Morganroth J, Brumpt I, et al. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. J Antimicrob Chemother. 1996;37(Suppl A):161-167.